Merrimack Pharmaceuticals Profile

13.12
USD 0.37  2.9%
12.75Last Month High 15.09 
12.95Trading Day  High 13.34 

Acquisition by John Dineen of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Dineen, the corporate stakeholder, on September 15, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Merrimack Pharmaceuticals Summary

Merrimack Pharmaceuticals Inc (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 426 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 178.21 M. Merrimack Pharmaceuticals Inc has 13.28 M outstanding shares of which 25.17 M shares are now shorted by private and institutional investors with about 18.07 trading days to cover. Merrimack Pharmac currently holds about 135.5 M in cash with (161.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.2.
Check Merrimack Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Lejeune Puetz Investment Counsel LlcCommon Shares4.3 K213 K
Horrell Capital Management IncCommon Shares50.01000
Highbridge Capital Management LlcDebt25.8 M19.2 M
View Merrimack Pharmaceuticals Diagnostics

Selected Merrimack Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Merrimack Pharmaceuticals Against Markets

Current Ratings  

Merrimack Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
< 90% 
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameMerrimack Pharmaceuticals Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business AddressOne Kendall Square, Suite B7201, Cambridge, MA 02139, United States
Foreign Associate  India
ExchangeNASDAQ General Markets
CIK Number01274792.0
CUSIP590328100
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.merrimack.com
Contact Number617 441 1000
CurrencyUSD - US Dollar

Recommendations

Merrimack Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
6.0Hold2Odds
Merrimack Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Merrimack Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Merrimack Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.22March 1, 2017
Merrimack Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate